Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer.
Shaogang Wang,Zhihua Wang,Zhiquan Hu,Chunguang Yang
DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.tps233
IF: 45.3
2024-02-01
Journal of Clinical Oncology
Abstract:TPS233 Background: To prevent ‘flare-up’ phenomenon, mainstream guidelines recommend offering a first-generation antiandrogen for ≥7 days to metastatic prostate cancer starting GnRH agonist. Our previous study found that in the 3-day regimen of a new AR antagonist apalutamide (that is, GnRH agonist was given 3 days after application of apalutamide), PSA decreased by 5-10% on day 1, and PSA decreased by about 1/3 after 3 days of oral administration, which was equivalent to the inhibition of PSA synthesis by bicalutamide for 4 weeks, and no clinical symptoms were worsened. Since the blood concentration of the new AR antagonists could reach nearly 80% of the peak concentration after 1 hour of oral administration, our research group further tried the 1-hour regimen (that is, GnRH agonist was given after 1 hour of application of apalutamide), and 8 patients showed an increase in serum testosterone, but no increase in PSA and aggravation of clinical symptoms, which initially indicated the feasibility of the 1-hour regimen. The objective of this study is to explore the efficacy and mechanism of the combined application of rezvilutamide and GnRH agonist (Goserelin Microspheres for Injection) on mHSPC to prevent flare-up. Methods: This is a multicenter, prospective, randomized controlled study (ChiCTR2300076106). Key inclusion criteria: Age ≥ 18 years, first diagnosis of prostate adenocarcinoma by histologically confirmed within 1 month; at least one distant metastasis (extrinsic pelvic lymph node metastasis, bone metastasis, or visceral metastasis); PSA ≥ 2ng/ml and serum testosterone ≥ 150ng/dl. Sixty mHSPC patients are expected to be enrolled and treated with rezvilutamide combined with GnRH agonist. The patients will be randomized 1:1 into the 1-day regimen (oral rezvilutamide 1 day in advance) and the 1-hour regimen (oral rezvilutamide 1 hour in advance) with 30 patients each. The GnRH agonist treatment is 3.6 mg Goserelin Microspheres for Injection i.m. every 4 weeks. Collect patient baseline data: Age, tumor size, pathological classification, TNM stage, Gleason score, clinical symptoms, PSA level, testosterone level. Periodic review of laboratory tests (PSA, LH, testosterone, etc.), imaging changes (magnetic resonance, CT, PET/CT, etc.), changes in clinical symptoms, changes in survival status, etc. The occurrence of flare-up effects and hormone levels on day 1, day 3, day 7, day 14, and day 28 after medication will be described. Kaplan-Meier survival analysis and Cox proportional-hazards model were used to evaluate the above indicators. Clinical trial information: ChiCTR2300076106 .
oncology